PARP inhibitors combined with antibodies against PD-L1 show synergistic effects in breast cancer cells and PDXs (Jiao et al. 2017) as well as ovarian and colon-cancer mouse models (Ding et al. 2018; Shen et al. 2019). Here, PARP1 is linked to breast carcinoma.